[1] Ostrom Q T, Gittleman H, Kruchko C, Louis D N, Brat D J, Gilbert M R, et al. Completeness of required site-specific factors for brain and CNS tumors in the surveillance, epidemiology and end results (SEER) 18 database (2004-2012, varying). J Neuro-Oncol. 2016; 130(1): 31-42.
[2] Hambardzumyan D, Gutmann D H and Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 2016; 19(1): 20-7.
[3] Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12): 677–86.
[4] Verreck F A, de Boer T, Langenberg D M, Hoeve M A, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci USA. 2004; 101(13): 4560–65.
[5] Hu G, Drescher K M, and Chen X M. Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet. 2012; 3: 56.
[6] Purushothaman A, Bandari S K, Liu J, Mobley J A, Brown E E and Sanderson R D. Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. J Biol Chem. 2016; 291(4): 1652–63.
[7] Gurunathan S, Kang M H, Jeyaraj M, Qasim M and Kim J H. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. Cells. 2019;8(4): E307.
[8] Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty A L, Ott M, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4): e1412909.
[9] Palumbo S, Miracco C, Pirtoli L and Comincini S. Emerging Roles of microRNA in Modulating Cell-Death Processes in Malignant Glioma. J Cell Physiol. 2013; 229(3): 277-286.
[10] Masri S, and Sassone-Corsi P, The emerging link between cancer, metabolism, and circadian rhythms. Nat Med. 2018; 24(12): 1795-803.
[11] Papantoniou K, Castaño-Vinyals G, Espinosa A, Aragonés N, Pérez-Gómez B and Burgos J. Night shift work, chronotype and prostate cancer risk in the MCCSpain case-control study. Int J Cancer. 2015; 137(5): 1147-57.
[12] Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007; 8(12): 1065-6.
[13] Yuan Y, Wu S, Li W, He W. A Tissue-Specific Rhythmic Recruitment Pattern of Leukocyte Subsets. Front Immunol. 2020;11.
[14] Hergenhan S, Holtkamp S, and Scheiermann C. Molecular Interactions Between Components of the Circadian Clock and the Immune System. J Mol Biol. 2020 Jan 10.
[15] da Fonseca A C and Badie B, Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin. Dev. Immunol. 2013: 264124.
[16] Lisi L, Ciotti G M, Braun D, Kalinin S, Currò D, Dello Russo C, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci Lett. 2017; 645:106-12.
[17] Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006; 97(7): 589-96.
[18] Li X, Wang S, Yang S, Ying J, Yu H, Yang C, Liu Y, et al. Circadian locomotor output cycles kaput affects the proliferation and migration of breast cancer cells by regulating the expression of E-cadherin via IQ motif containing GTPase activating protein 1. Oncol Lett. 2018; 15(5): 7097-103.
[19] Mazzoccoli G, Panza A, Valvano M R, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011; 28(10): 841-51.
[20] Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J, Higashimoto M, Mashiko M, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87(10): 1060-70.
[21] Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ and Arafat H A. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J Gastrointest Surg. 2013; 17(3): 443-50.
[22] Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C and Lymberi M. Expression of clock genes in patients with colorectal cancer. Int J Biol Markers. 2013; 28(3): 280-5.
[23] Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profifiles classify human cancers. Nature. 2005; 435: 834-8.
[24] Cordonnier M, Chanteloup G, Isambert N, Seigneuric R, Fumoleau P, Garrido C, et al. Exosomes in cancer theranostic: Diamonds in the rough. Cell Adh Migr. 2017; 11(2): 151-63.
[25] Tkach M and Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016; 164(6): 1226-32.
[26] Wheelock M J and Johnson K R. Cadherins as Modulators of Cellular Phenotype. Annual Review of Cell and Developmental Biology. Cell Res. 2003;19(1): 207-35.
[27] Lamouille S, Xu J and Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3): 178-96.
[28] Singh S, Sadacharan S, Su S, Belldegrun A, Persad S and Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 2003; 63(9): 2306-11.